DOCSLIB.ORG

We Have Some Trouble with Special Characters and Displaying Monographs. 22.09.2018 ATC Code: G03FA17 Classification

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
We Have Some Trouble with Special Characters and Displaying Monographs. 22.09.2018 ATC Code: G03FA17 Classification We have some trouble with special characters and displaying monographs. 22.09.2018 ATC code: G03FA17 Classification: PRP - Probably porphyrinogenic Substance: Drospirenone and estrogen Rationale for risk classification: Estrogens and progestogens are considered as potentially porphyrinogenic substances and are known to have caused porphyric attacks in susceptible carriers of acute porphyria. Both pharmacodynamic and pharmacokinetic properties can explain the triggering effect in acute porphyria. Studies have shown that these hormones can affect CYP enzymes by induction and mechanism-based inhibition. Although these effects are described to a limited extent in drug-drug interactions studies in general, it is likely that they have a role in a probable upregulation of the heme biosynthesis. Chemical description: Drospirenone is a spironolactone derivative. Estradiol is a natural steroid hormone. Therapeutic characteristics: Continuous monophasic hormone replacement therapy (HRT). It is administered orally. Side effects or other pharmacodynamic effetcs of relevance to acute porphyria: A suggested hypothesis for the porphyrinogenic potential of progestins (Thunell 2016) is that they activate the mPRalpha-PGRMC2 receptor complex (Thomas 2013), which is accompanied by heme binding (Rohe 2009), and may therefore result in a heme drain. A decreased cellular heme pool may then upregulate ALAS-1 (Besur 2014). In addition, the heme-sensing receptor, Rev-erb-alpha, will sense the decreased level of the regulatory heme pool and reduce its repressor effect on PGC-1alpha (Wu 2009). PGC-1alpha may then co-activate FoxO1 and NRF-1, with subsequent induction of the ALAS-1 gene (Handschin 2005). An in vitro study found that estrogens might directly activate ALAS-1 (Du Plessis 2009). In the presence of estrogen, the estrogen receptor-alpha (ER-alpha) binds to estrogen receptor elements (ERE) in the ALAS-1 Copyright 2007-2018 The Drug Database. All rights reserved.Page 1/6 promotor and results in an elevated transcription of ALAS-1 and thereby causing a subsequent increase in the rate of the entire heme biosynthesis pathway. Metabolism and pharmacokinetics: Estradiol is predominantly metabolized in the liver to estrone and then to estriol (SPC). CYP1A2 and 3A4 are involved in the hydroxylation of estradiol to estriol, which is further glucuronidated. Estradiol and its metabolites are mainly excreted by the kidneys (SPC). Estradiol is not found to be an inhibitor of CYP2C9, CYP2C19 and CYP3A4, and compared to ethinyl estradiol, it is less likely to cause mechanism-based inhibition due to the lack of an acetylenic group (Laine 2003). Estradiol is listed as an activator of human PXR (Honkakoski 2003, Mnif 2007) and has been found to induce CYP2A6 in vitro (Higasi 2007). Drospirenone is metabolized by opening of the lactone ring, and by reduction and subsequent sulfatation. Drospirenone is also subject to oxidative metabolism catalyzed by CYP3A4. In vitro, drospirenone is a weak to moderate inhibitor of CYP1A1, CYP2C9, CYP2C19 and CYP3A4 (SPC). Progesterone and synthetic progestogens activate PXR (Kliewer 1998). Progestogens and estradiol are not listed as significant inducers of CYP 3A4 in most interaction databases (Preissner 2010, NOMA, Lexi-Interact, The Danish Health and Medicines Authority, Micromedex). Results from clinical studies suggest that the increased hormonal levels in pregnancy have the potential to alter hepatic cytochrome P450 drug metabolism (Anderson 2005). Also, in vitro studies have shown increased CYP mRNA after exposing hepatocytes to progesterone and estradiol levels equal to the high hormonal levels typically seen in the third trimester of pregnancy (Choi 2013). Hormonal therapy generally leads to a much lower plasma concentration relative to the levels of endogenous hormones in pregnancy and may explain the lack of observed significant effects of administered hormones on CYP 3A4 in vivo. However, since both estradiol and the progestin component have the potential to induce ALAS1 through PXR activation and at the same time cause inhibition of CYP 3A4, this may explain the absence of observed pharmacokinetic drug-drug interactions. For an evaluation of the porphyrinogenicity of these drugs it is important to realize that the inhibitory effect can mask the inductive power and that an Copyright 2007-2018 The Drug Database. All rights reserved.Page 2/6 increased de novo synthesis of CYP3A4 can take place irrespective of negative results from in vivo DDI-studies. The effects of concomitant induction and inhibition have in general been discussed by Wei et al. for other drugs (Wei 2016). Since CYP3A4 quantitatively is the largest CYP isoenzyme, an increased de novo synthesis of CYP3A4, although masked, will give an upregulation of ALAS-1and thereby a higher flux through the heme biosynthesis. Such a mechanism can possibly in part explain the observed porphyrinogenic effects of these drugs. Studies have shown that women with acute porphyria have an altered 5alfa-reductase steroid metabolism and it is suggested that this may lead to a diversion from the 5 alfa reductase pathway to formation of 5beta steroid metabolites that may be more potent inductors of ALAS1 (Innala 2012, Anderson 1979, Jacobs 2005). Published clinical experience: It is from clinical observations well known that progestogens and estrogens have a role in precipitating acute porphyric attacks (Andersson 2003, Kauppinen 1992, Bonkovsky 2014). References: Andersson C, Innala E, et al. Acute intermittent porphyria in women: clinical expression, use and experience of exogenous sex hormones. A population-based study in northern Sweden. J Intern Med. 2003 Aug;254(2):176-83. Anderson GD. Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. Clin Pharmacokinet. 2005;44(10):989-1008. Anderson KE, Bradlow HL, et al. Studies in porphyria. VIII. Relationship of the 5 alpha-reductive metabolism of steroid hormones to clinical expression of the genetic defect in acute intermittent porphyria. Am J Med. 1979 Apr;66(4):644-50. Besur S, Hou W, et al. Clinically important features of porphyrin and heme metabolism and the porphyrias. Metabolites. 2014 Nov 3;4(4):977-1006. Bonkovsky HL, Maddukuri VC et al. Acute porphyrias in the USA: features of 108 subjects from porphyrias consortium. Am J Med. 2014 Dec;127(12):1233-41. Copyright 2007-2018 The Drug Database. All rights reserved.Page 3/6 Du Plessis N, Kimberg M, et al. Functional analysis of the 5' regulatory region of the 5-aminolevulinate synthase (ALAS1) gene in response to estrogen. Cell Mol Biol (Noisy-le-grand). 2009 Jul 1;55(2):20-30. Higashi E, Fukami T, et al. Human CYP2A6 is induced by estrogen via estrogen receptor. Drug Metab Dispos. 2007 Oct;35(10):1935-41. Epub 2007 Jul 23. Handschin C, Lin J, et al. Nutritional regulation of hepatic heme biosynthesis and porphyria through PGC-1alpha. Cell. 2005 Aug 26;122(4):505-15. Honkakoski P, Sueyoshi T, et al. Drug-activated nuclear receptors CAR and PXR. Ann Med. 2003;35(3):172-82. Innala E, Bäckström T et al. Women with acute intermittent porphyria have a defect in 5?-steroid production during the menstrual cycle. Acta Obstet Gynecol Scand. 2012 Dec;91(12):1445-52. Jacobs MN, Nolan GT, Hood SR. Lignans, bacteriocides and organochlorine compounds activate the human pregnane X receptor (PXR). Toxicol Appl Pharmacol. 2005 Dec 1;209(2):123-33 Kauppinen R, Mustajoki P. Prognosis of acute porphyria: occurrence of acute attacks, precipitating factors, and associated diseases. Medicine (Baltimore). 1992 Jan;71(1):1-13. Kliewer SA, Moore JT, et al. An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell. 1998 Jan 9;92(1):73-82. Lexi-Interact in UpToDate: Drug interaction program. http://www.micromedexsolutions.com/ (Accessed 23.08.2017). Mnif W, Pascussi JM, et al. Estrogens and antiestrogens activate hPXR. Toxicol Lett. 2007 Apr Copyright 2007-2018 The Drug Database. All rights reserved.Page 4/6 5;170(1):19-29. Epub 2007 Feb 16. Micromedex® 2.0 (online). Drug Interactions). http://www.helsebiblioteket.no/ (23.08.2017). Norwegian medicines agency (NOMA). Find medicine. http://www.legemiddelverket.no/interaksjonssok (Accessed: 23.08.2017). Preissner S, Kroll K, rt al. SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Rohe HJ, Ahmed IS, et al. PGRMC1 (progesterone receptor membrane component 1): a targetable protein with multiple functions in steroid signaling, P450 activation and drug binding. Pharmacol Ther. 2009 Jan;121(1):14-9. The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Angeliq. http://www.medicines.org.uk/EMC/. (Last edition: 31.08.2017). The Danish Health and Medicines Authority. The drug interaction database. http://www.interaktionsdatabasen.dk/ (Accessed: 23.08.2017). Thomas P, Pang Y, et al. Enhancement of cell surface expression and receptor functions of membrane progestin receptor alpha (mPRalpha) by progesterone receptor membrane component 1 (PGRMC1): evidence for a role of PGRMC1 as an adaptor protein for steroid receptors. Endocrinology. 2014 Mar;155(3):1107-19. Thunell S. Genetik och metabola förlopp bakom den akuta porfyriattacken - Mer än hundra läkemedel är potentiellt livshotande vid akut porfyri. Lakartidningen. 2016 Sep 9;113. Wei Y, Tang C, et al. A Molecular Aspect in the Regulation of Drug Metabolism: Does PXR-Induced Enzyme Expression Always Lead to Functional Changes in Drug Metabolism? Curr Pharmacol Rep. 2016 Aug;2(4):187-192. Copyright 2007-2018 The Drug Database. All rights reserved.Page 5/6 Wu N, Yin L, et al. Negative feedback maintenance of heme homeostasis by its receptor, Rev-erbalpha. Genes Dev. 2009 Sep 15;23(18):2201-9 Copyright 2007-2018 The Drug Database. All rights reserved.Page 6/6.
Load more

Recommended publications
  • Insulin Receptor Plasma Membrane Levels Increased by the Progesterone Receptor Membrane Component 1 S
    Supplemental material to this article can be found at: http://molpharm.aspetjournals.org/content/suppl/2018/04/19/mol.117.110510.DC1 1521-0111/94/1/665–673$35.00 https://doi.org/10.1124/mol.117.110510 MOLECULAR PHARMACOLOGY Mol Pharmacol 94:665–673, July 2018 Copyright ª 2018 by The American Society for Pharmacology and Experimental Therapeutics Insulin Receptor Plasma Membrane Levels Increased by the Progesterone Receptor Membrane Component 1 s Kaia K. Hampton, Katie Anderson, Hilaree Frazier, Olivier Thibault, and Rolf J. Craven Department of Pharmacology and Nutritional Sciences, Markey Cancer Center, University of Kentucky College of Medicine, Lexington, Kentucky Received September 7, 2017; accepted April 13, 2018 Downloaded from ABSTRACT The insulin receptor (IR) is a ligand-activated receptor tyrosine therapeutic applications because a small-molecule PGRMC1 kinase that has a key role in metabolism, cellular survival, and ligand, AG205, also decreases plasma membrane IR levels. proliferation. Progesterone receptor membrane component However, PGRMC1 knockdown via short hairpin RNA expres- 1 (PGRMC1) promotes cellular signaling via receptor trafficking sion and AG205 treatment potentiated insulin-mediated phos- and is essential for some elements of tumor growth and phorylation of the IR signaling mediator AKT. Finally, PGRMC1 metastasis. In the present study, we demonstrate that PGRMC1 also increased plasma membrane levels of two key glucose molpharm.aspetjournals.org coprecipitates with IR. Furthermore, we show that PGRMC1 transporters, GLUT-4 and GLUT-1. Our data support a role for increases plasma membrane IR levels in multiple cell lines and PGRMC1 maintaining plasma membrane pools of the receptor, decreases insulin binding at the cell surface.
    [Show full text]
  • Progesterone Receptor Membrane Component 1 Promotes Survival of Human Breast Cancer Cells and the Growth of Xenograft Tumors
    Cancer Biology & Therapy ISSN: 1538-4047 (Print) 1555-8576 (Online) Journal homepage: http://www.tandfonline.com/loi/kcbt20 Progesterone receptor membrane component 1 promotes survival of human breast cancer cells and the growth of xenograft tumors Nicole C. Clark, Anne M. Friel, Cindy A. Pru, Ling Zhang, Toshi Shioda, Bo R. Rueda, John J. Peluso & James K. Pru To cite this article: Nicole C. Clark, Anne M. Friel, Cindy A. Pru, Ling Zhang, Toshi Shioda, Bo R. Rueda, John J. Peluso & James K. Pru (2016) Progesterone receptor membrane component 1 promotes survival of human breast cancer cells and the growth of xenograft tumors, Cancer Biology & Therapy, 17:3, 262-271, DOI: 10.1080/15384047.2016.1139240 To link to this article: http://dx.doi.org/10.1080/15384047.2016.1139240 Accepted author version posted online: 19 Jan 2016. Published online: 19 Jan 2016. Submit your article to this journal Article views: 49 View related articles View Crossmark data Full Terms & Conditions of access and use can be found at http://www.tandfonline.com/action/journalInformation?journalCode=kcbt20 Download by: [University of Connecticut] Date: 26 May 2016, At: 11:28 CANCER BIOLOGY & THERAPY 2016, VOL. 17, NO. 3, 262–271 http://dx.doi.org/10.1080/15384047.2016.1139240 RESEARCH PAPER Progesterone receptor membrane component 1 promotes survival of human breast cancer cells and the growth of xenograft tumors Nicole C. Clarka,*, Anne M. Frielb,*, Cindy A. Prua, Ling Zhangb, Toshi Shiodac, Bo R. Ruedab, John J. Pelusod, and James K. Prua aDepartment of Animal Sciences,
    [Show full text]
  • To Download the 2021 Annual Meeting Final Program!
    Final Program JULY 6 - 9, 2021 | BOSTON, MA MARRIOTT COPLEY PLACE VIRTUAL OPTION AVAILABLE NAVIGATING THE FUTURE FOR REPRODUCTIVE SCIENCE Society for Reproductive Investigation 68th Annual Scientific Meeting Photo Credit: Kyle Klein Table of Contents Message from the SRI President .............................................................................................................1 2021 Program Committee ......................................................................................................................2 General Meeting Information .................................................................................................................3 Meeting Attendance Code of Conduct Policy ..........................................................................................5 Schedule-at-a-Glance ............................................................................................................................7 Boston Information and Social Events ....................................................................................................8 Exhibitors ...............................................................................................................................................9 Hotel Map ............................................................................................................................................10 Continuing Medical Education Information ..........................................................................................11 Scientific Program
    [Show full text]
  • PGRMC1 and PGRMC2 in Uterine Physiology and Disease
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Frontiers - Publisher Connector PERSPECTIVE ARTICLE published: 19 September 2013 doi: 10.3389/fnins.2013.00168 PGRMC1 and PGRMC2 in uterine physiology and disease James K. Pru* and Nicole C. Clark Department of Animal Sciences, School of Molecular Biosciences, Center for Reproductive Biology, Washington State University, Pullman, WA, USA Edited by: It is clear from studies using progesterone receptor (PGR) mutant mice that not all of Sandra L. Petersen, University of the actions of progesterone (P4) are mediated by this receptor. Indeed, many rapid, Massachusetts Amherst, USA non-classical P4 actions have been reported throughout the female reproductive tract. Reviewed by: Progesterone treatment of Pgr null mice results in behavioral changes and in differential Cecily V. Bishop, Oregon National Primate Research Center, USA regulation of genes in the endometrium. Progesterone receptor membrane component Christopher S. Keator, Ross (PGRMC) 1 and PGRMC2 belong to the heme-binding protein family and may serve as University School of Medicine, P4 receptors. Evidence to support this derives chiefly from in vitro culture work using Dominica primary or transformed cell lines that lack the classical PGR. Endometrial expression of *Correspondence: PGRMC1 in menstrual cycling mammals is most abundant during the proliferative phase James K. Pru, Department of Animal Sciences, School of Molecular of the cycle. Because PGRMC2 expression shows the most consistent cross-species Biosciences, Center for expression, with highest levels during the secretory phase, PGRMC2 may serve as a Reproductive Biology, Washington universal non-classical P4 receptor in the uterus.
    [Show full text]
  • Progesterone – Friend Or Foe?
    Frontiers in Neuroendocrinology 59 (2020) 100856 Contents lists available at ScienceDirect Frontiers in Neuroendocrinology journal homepage: www.elsevier.com/locate/yfrne Progesterone – Friend or foe? T ⁎ Inger Sundström-Poromaaa, , Erika Comascob, Rachael Sumnerc, Eileen Ludersd,e a Department of Women’s and Children’s Health, Uppsala University, Sweden b Department of Neuroscience, Science for Life Laboratory, Uppsala University, Uppsala, Sweden c School of Pharmacy, University of Auckland, New Zealand d School of Psychology, University of Auckland, New Zealand e Laboratory of Neuro Imaging, School of Medicine, University of Southern California, Los Angeles, USA ARTICLE INFO ABSTRACT Keywords: Estradiol is the “prototypic” sex hormone of women. Yet, women have another sex hormone, which is often Allopregnanolone disregarded: Progesterone. The goal of this article is to provide a comprehensive review on progesterone, and its Emotion metabolite allopregnanolone, emphasizing three key areas: biological properties, main functions, and effects on Hormonal contraceptives mood in women. Recent years of intensive research on progesterone and allopregnanolone have paved the way Postpartum depression for new treatment of postpartum depression. However, treatment for premenstrual syndrome and premenstrual Premenstrual dysphoric disorder dysphoric disorder as well as contraception that women can use without risking mental health problems are still Progesterone needed. As far as progesterone is concerned, we might be dealing with a two-edged sword: while its metabolite allopregnanolone has been proven useful for treatment of PPD, it may trigger negative symptoms in women with PMS and PMDD. Overall, our current knowledge on the beneficial and harmful effects of progesterone is limited and further research is imperative. Introduction 1.
    [Show full text]
  • Loss of PGRMC1 Delays the Progression of Hepatocellular Carcinoma Via Suppression of Pro-Inflammatory Immune Responses
    cancers Article Loss of PGRMC1 Delays the Progression of Hepatocellular Carcinoma via Suppression of Pro-Inflammatory Immune Responses Sang R. Lee 1,† , Jong Geol Lee 2,†, Jun H. Heo 1, Seong Lae Jo 1, Jihoon Ryu 1 , Globinna Kim 2, Jung-Min Yon 2, Myeong Sup Lee 3, Geun-Shik Lee 4 , Beum-Soo An 5 , Hyun-Jin Shin 1, Dong-Cheol Woo 2 , In-Jeoung Baek 2,* and Eui-Ju Hong 1,* 1 College of Veterinary Medicine, Chungnam National University, Daejeon 34134, Korea; [email protected] (S.R.L.); [email protected] (J.H.H.); [email protected] (S.L.J.); [email protected] (J.R.); [email protected] (H.-J.S.) 2 Department of Convergence Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Korea; [email protected] (J.G.L.); [email protected] (G.K.); [email protected] (J.-M.Y.); [email protected] (D.-C.W.) 3 Department of Biomedical Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Korea; [email protected] 4 College of Veterinary Medicine, Kangwon National University, Chuncheon, Gangwon 24341, Korea; [email protected] 5 Department of Biomaterials Science, College of Natural Resources & Life Science, Pusan National University, Miryang, Gyeongsangnam 50463, Korea; [email protected] * Correspondence: [email protected] (I.-J.B.); [email protected] (E.-J.H.); Tel.: +82-2-3010-2798 (I.-J.B.); Citation: Lee, S.R.; Lee, J.G.; Heo, +82-42-821-6781 (E.-J.H.); Fax: +82-2-3010-4197 (I.-J.B.); +82-42-821-8903 (E.-J.H.) J.H.; Jo, S.L.; Ryu, J.; Kim, G.; Yon, † These authors equally contributed to the study.
    [Show full text]
  • P338. Does Norethisterone Stimulate Human Breast Cancer Cells Proliferation by Promoting PGRMC1 Expression?
    P338. Does Norethisterone stimulate human breast cancer cells proliferation by promoting PGRMC1 expression? M Gu (CN) [1], X Ruan (CN) [2], C Jia (CN) [3], C Yang (CA) [4], P Hardy (CA) [5], A O Mueck (DE) [6] Context : Important studies such as the Women’s Health Initiative (WHI) and the Million Women Study (MWS) showed progestogens may play a important role in the development of breast cancer under hormone therapy in menopausal women. Progesterone receptor membrane component 1 (PGRMC1) has been found to be highly expressed in the tissue of breast cancer patients.in our previous studys,we found norethisterone (NET) can stimulate the proliferation of breast cancer cells which express PGRMC1 in vitro and in vivo,However the mechanism is unclear. Objective: To investigate possible mechanisms for increased breast cancer risk with NET in hormone therapy and oral contraceptives. Methods: Cell viability assay was performed to investigate the proliferation effect of MCF-7 cells stimulated with NET or progesterone (10-5 M~10-11 M).Quantitative PCR and Western blot analysis were used to evaluate the PGRMC1 expression in three groups. The promoter sequence of PGRMC1(2kb) was cloned into pGL3-basic reporter vector. Cells were transfected with plasmids using FuGene. Luciferase activity was determined 48 hours posttransfection with the Dual-Luciferase Reporter Assay System . Results: NET induced MCF-7 cell viability dose-dependently, but this effect was not observed by using progesterone. Our real-time quantitative PCR data displayed the significantly increase mRNA level of PGRMC1 in the MCF-7 cells stimulated with NET dose-dependently. Western blot analysis show that expression of PGRMC1 in protein level significantly increase in the MCF-7 cells stimulated with NET compare to MCF-7 cells stimulated with progesterone.We found NET up-regulated the activity of the PGRMC1 promoter.
    [Show full text]
  • Progesterone Receptor Membrane Component 1 Suppresses the P53
    www.nature.com/scientificreports OPEN Progesterone Receptor Membrane Component 1 suppresses the p53 and Wnt/β-catenin pathways to Received: 30 October 2017 Accepted: 2 February 2018 promote human pluripotent stem Published: xx xx xxxx cell self-renewal Ji Yea Kim1, So Young Kim1, Hong Seo Choi1, Min Kyu Kim1, Hyun Min Lee1, Young-Joo Jang2 & Chun Jeih Ryu1 Progesterone receptor membrane component 1 (PGRMC1) is a multifunctional heme-binding protein involved in various diseases, including cancers and Alzheimer’s disease. Previously, we generated two monoclonal antibodies (MAbs) 108-B6 and 4A68 against surface molecules on human pluripotent stem cells (hPSCs). Here we show that PGRMC1 is the target antigen of both MAbs, and is predominantly expressed on hPSCs and some cancer cells. PGRMC1 is rapidly downregulated during early diferentiation of hPSCs. Although PGRMC1 knockdown leads to a spread-out morphology and impaired self-renewal in hPSCs, PGRMC1 knockdown hPSCs do not show apoptosis and autophagy. Instead, PGRMC1 knockdown leads to diferentiation of hPSCs into multiple lineage cells without afecting the expression of pluripotency markers. PGRMC1 knockdown increases cyclin D1 expression and decreases Plk1 expression in hPSCs. PGRMC1 knockdown also induces p53 expression and stability, suggesting that PGRMC1 maintains hPSC self-renewal through suppression of p53-dependent pathway. Analysis of signaling molecules further reveals that PGRMC1 knockdown promotes inhibitory phosphorylation of GSK-3β and increased expression of Wnt3a and β-catenin, which leads to activation of Wnt/β-catenin signaling. The results suggest that PGRMC1 suppresses the p53 and Wnt/β-catenin pathways to promote self-renewal and inhibit early diferentiation in hPSCs.
    [Show full text]
  • PGRMC1 Phosphorylation Status and Cell Plasticity 1: Glucose Metabolism, Mitochondria
    bioRxiv preprint doi: https://doi.org/10.1101/737718; this version posted August 24, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Title PGRMC1 phosphorylation status and cell plasticity 1: glucose metabolism, mitochondria, and mouse xenograft tumorigenesis Authors Bashar M. Thejer,1,2,3 Partho P. Adhikary,1,2,4 Amandeep Kaur,5,6 Sarah L. Teakel,1 Ashleigh Van Oosterum,7 Ishith Seth,1 Marina Pajic,8,9 Kate M. Hannan,10,11 Megan Pavy,11 Perlita Poh,11 Jalal A. Jazayeri,1 Thiri Zaw,12 Dana Pascovici,12 Marina Ludescher,13 Michael Pawlak,14 Juan C. Cassano,15 Lynne Turnbull,16 Mitra Jazayeri,17 Alexander C. James,18,19,20 Craig P. Coorey,18,21 Tara L. Roberts,18,19,20,21 Simon J. Kinder,22 Ross D. Hannan,9,10,23,24,25 Ellis Patrick,26 Mark P. Molloy,12,27 Elizabeth J. New,5 Tanja N. Fehm,13 Hans Neubauer,13 Ewa M. Goldys,28,29 Leslie A. Weston,30,31 and Michael A. Cahill.1,10,* Affiliations 1. School of Biomedical Sciences, Charles Sturt University, Wagga Wagga, NSW, 2650, Australia. 2. Co-first author. 3. Department of Biology, College of Science, University of Wasit, Wasit, Iraq. 4. Current address: Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, Canada. 5. University of Sydney, School of Chemistry, Sydney, NSW, 2006 Australia.
    [Show full text]
  • Ated Progesterone Receptor Component 2 (PGRMC-2) in Matur
    Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 26 July 2021 doi:10.20944/preprints202107.0555.v1 Article Molecular Characterization of a Functional Membrane-Associ- ated Progesterone Receptor Component 2 (PGRMC-2) in Matur- ing Oocytes of the Human Parasite Nematode Trichinella spi- ralis: Implications to the Host-Parasite Relationship Jorge Morales-Montor 1, *, Álvaro Colin-Oviedo 2, Gloria María. González-González 2, José Prisco Palma-Nicolás 2, Alejandro Sánchez-González 2, Karen Elizabeth Nava-Castro 3, Lenin Dominguez-Ramirez 4, Martín García-Va- 5 6 2, rela , Víctor Hugo Del Río-Araiza and Romel Hernández-Bello * 1 Departamento de Inmunología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, AP 70228, Ciudad de México 04510, México.; [email protected] 2 Departamento de Microbiología, Facultad de Medicina, Universidad Autónoma de Nuevo León, Monterrey. P 64460. Nuevo León, México.; [email protected] (A.C.O); [email protected] (G.M.G.G); jose.pal- [email protected] (J.P.P.N); [email protected] (A.S.G); [email protected] (R.H.B). 3 Laboratorio de Genotoxicología y Medicina Ambientales. Departamento de Ciencias Ambientales. Centro de Ciencias de la Atmósfera. Universidad Nacional Autónoma de México. 04510. Ciudad de México, Mé- xico.; [email protected] 4 Departamento de Ciencias Químico-Biológicas, Universidad de las Américas Puebla, Sta. Catarina Mártir, Cholula, C.P 72810 Puebla, México.; [email protected] 5 Instituto de Biología, Universidad Nacional Autónoma de México, Ciudad de México 04510, México.; gar- [email protected] 6 Departamento de Parasitología, Facultad de Medicina Veterinaria y Zootecnia, Universidad Nacional Autó- noma de México, Ciudad de México 04510, México.; [email protected] * Correspondence: [email protected] ; Tel.: (+52 (81) 8329-4177; R.H.B), jmontor66@bio- medicas.unam.mx ; Tel.: (+52555-56223158, Fax: +52555-56223369; J.M.M).
    [Show full text]
  • The Evolutionary Appearance of Signaling Motifs in PGRMC1
    BioScience Trends Advance Publication P1 Original Article Advance Publication DOI: 10.5582/bst.2017.01009 The evolutionary appearance of signaling motifs in PGRMC1 Michael A. Cahill* School of Biomedical Sciences, Charles Sturt University, Wagga Wagga, Australia. Summary A complex PGRMC1-centred regulatory system controls multiple cell functions. Although PGRMC1 is phosphorylated at several positions, we do not understand the mechanisms regulating its function. PGRMC1 is the archetypal member of the membrane associated progesterone receptor (MAPR) family. Phylogentic comparison of MAPR proteins suggests that the ancestral metazoan "PGRMC-like" MAPR gene resembled PGRMC1/PGRMC2, containing the equivalents of PGRMC1 Y139 and Y180 SH2 target motifs. It later acquired a CK2 site with phosphoacceptor at S181. Separate PGRMC1 and PGRMC2 genes with this "PGRMC-like" structure diverged after the separation of vertebrates from protochordates. Terrestrial tetrapods possess a novel proline-rich PGRMC1 SH3 target motif centred on P64 which in mammals is augmented by a phosphoacceptor at PGRMC1 S54, and in primates by an additional S57 CK2 site. All of these phosphoacceptors are phosphorylated in vivo. This study suggests that an increasingly sophisticated system of PGRMC1-modulated multicellular functional regulation has characterised animal evolution since Precambrian times. Keywords: Phosphorylation, evolution, steroid signalling, kinases, metazoan 1. Introduction that regulates synthesis of sterol precursors, conferring responsiveness to progesterone
    [Show full text]
  • Secretion and Expression Regulation of Progesterone Receptor Membrane Component1 (PGRMC1) in Breast Cancer Cells
    Secretion and expression regulation of progesterone receptor membrane component1 (PGRMC1) in breast cancer cells Inaugural-Dissertation zur Erlangung des Doktorgrades der Medizin der Medizinischen Fakultät der Eberhard Karls Universität zu Tübingen vorgelegt von Bo Ma aus Zhejiang, China 2015 Dekan: Professor Dr. I. B. Autenrieth 1. Berichterstatter: Professor Dr. H. Seeger 2. Berichterstatter: Privatdozent Dr. E. Ruckhäberle Summary In women breast cancer still is the most prevalent cancer and one of the leading causes of death. Progesterone receptor membrane component-1 (PGRMC1) highly more expressed in cancerous breast tissue than in benign surrounding breast tissue may be involved in tumorigenesis and increase breast cancer risk. In recent investigations it could be shown that estrogens and certain synthetic progestogens can induce an increased proliferation rate in breast cancer cells via PGRMC1 suggesting a possible importance of the kind of estrogen and progestogen in terms of breast cancer risk when used as hormone therapy in the postmenopause. However, the detailed mechanisms through which PGMRC1 mediates proliferative effects elicited by progestogens and regulating its expression are still little known. It remained elusive whether PGRMC1 is secreted by breast cancer cells into plasma and thus might be used for cancer risk screening. Here we analyzed PGRMC1 expression and the proliferative effect of progestogens in various breast cancer cell lines. In BM cells (endogenous estrogen receptor (ER-α) and PGMRC1), medroxyprogesterone acetate (MPA), norethisterone (NET), levonorgestrel (LNG) and drospirenone (DRSP) significantly increased the proliferation. However, these progestogens didn’t obviously alter the proliferation of SUM225CWN cells (only endogenous PGRMC1). In MCF-7 breast cancer cells, the presence of PGRMC1 can sensitize E2-induced PS2 mRNA levels, an estrogen response element.
    [Show full text]